PD-1 is expressed in T lymphocytes and interferes with their activation when bound with their ligands PD-L1, inhibiting the effector phase and thus dampening the ability of these T cells to kill cancer cells (Keir et al., 2008; Gato-Canas et al., 2017; Zuazo et al., 2019). Here, PDCD1 is linked to cancer.